5-Lipoxygenase Gene Variants Are Not Associated With Atherosclerosis or Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis Cohort

Michael Y. Tsai, PhD; Jing Cao, PhD; Brian T. Steffen, PhDb; Natalie L. Weir, BS; Stephen S. Rich, PhD; Shuang Liang, PhD; Weihua Guan, PhD

Background—The arachidonate 5-lipoxygenase enzyme plays a crucial role in mediating inflammation to maintain homeostasis, yet certain allelic variants of the 5-lipoxygenase gene, ALOX5, may increase risk of atherosclerosis and coronary heart disease (CHD). Further, relations between ALOX5 and disease outcomes may be enhanced or attenuated depending on the bioavailability of 5-lipoxygenase enzyme substrates. By using a candidate gene approach in 6153 Multi-Ethnic Study of Atherosclerosis (MESA) participants, associations were determined among 1348 ALOX5 single nucleotide polymorphisms (SNPs) and carotid intima-media thickness (cIMT) as well as incident CHD, and interactions with plasma concentrations of arachidonic acid, eicosapentaenoic acid, or docosahexaenoic acid were tested.

Methods and Results—Multivariable linear regression was used to test for associations between cIMT and ALOX5 SNPs, and Cox regression was used for incident CHD. Bonferroni correction was used for multiple hypothesis testing. No significant associations between ALOX5 SNPs and cIMT or CHD events were observed. Levels of arachidonic acid, eicosapentaenoic acid, or docosahexaenoic acid concentrations did not modify the relations of ALOX5 with either outcome.

Conclusions—ALOX5 gene variants do not appear to be related to clinical CHD events or subclinical atherosclerosis regardless of bioavailable enzyme substrate levels in this multiethnic cohort. Further studies that directly examine protein expression or enzyme activity may better define the arachidonate 5-lipoxygenase pathway in disease development and progression. (J Am Heart Assoc. 2016;5:e002814 doi: 10.1161/JAHA.115.002814)

Key Words: ALOX5 • coronary heart disease • fatty acids • intima-media thickness

Arachidonate 5-lipoxygenase (5-LOX) is a well-characterized enzyme that mediates the conversion of arachidonic acid (AA) to leukotriene B4—a crucial step in the acute phase immune response in maintaining homeostasis. However, recent studies have indicated that 5-LOX activity may also promote pathophysiological events including atherogenesis and cardiovascular events. More specifically, single nucleotide polymorphisms (SNPs) in the gene encoding 5-LOX (ALOX5) have been shown to increase inflammatory leukotriene production, which may, in turn, have implications for promoting inappropriate or excessive vascular inflammation resulting in atherosclerosis and eventual coronary heart disease (CHD).  

To date, a number of well-powered case-control studies have examined associations of ALOX5 gene variants with metrics of atherosclerosis and CHD, yet findings have so far been inconclusive. Positive associations between ALOX5 and carotid intima-media thickness (cIMT) as well as coronary artery stenosis (>80%) were reported by Dwyer et al8 and Carlson et al,9 respectively. In one of the largest case-control studies,9 a variant in ALOX5 was shown to associate with the presence of coronary stenosis (>50%) in 3770 individuals; however, investigators were unable to replicate this result in a larger cohort of 13 152 participants of the Atherosclerosis Risk in Communities (ARIC) study.10 In the context of CHD event outcomes, null findings between ALOX5 and myocardial infarction (MI) were previously reported, although a follow-up interaction analysis...
revealed that certain ALOX5 alleles were related to MI but only in those with a high intake of AA. In total, evidence remains equivocal as to whether ALOX5 influences atherosclerosis or CHD, and further studies are needed.

To more thoroughly assess whether ALOX5 is related to atherosclerosis and CHD, a number of interaction terms must be considered. Specifically, levels of polyunsaturated fatty acids (PUFAs) such as AA and the marine omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may modify the relation of ALOX5 and CHD outcomes as suggested by previous studies. Finally, race/ethnicity remains an important consideration in genetic studies, but whether it may uncover or otherwise modify putative associations of ALOX5 gene variants and atherosclerosis or CHD outcomes has yet to be examined.

Overall, whether ALOX5 variants associate with atherosclerosis or CHD is unclear, and potential interactions with PUFAs and race/ethnicity have not been collectively studied in a large cohort population. The present analysis examines common ALOX5 gene SNPs and their cross-sectional association with subclinical atherosclerosis determined by common and internal cIMT values in 6153 participants of the Multi-Ethnic Study of Atherosclerosis (MESA). In addition, their associations with incident CHD during a median 8.5-year study period were also determined. and modifying influences of plasma phospholipid levels of AA, EPA, and DHA as well as race/ethnicity among black, white, Chinese American, and Hispanic participants were tested.

Methods

Study Population

The design of the MESA study has been described previously, and information about the MESA protocol is available at www.mesa-nhlbi.org. Briefly, 6814 men and women between the ages of 45 and 84 years without clinical evidence of cardiovascular disease were recruited from 6 communities in the United States. Institutional review board approval was obtained at all MESA sites, and all participants gave informed consent.

The current study excluded participants with missing covariates. The remaining study population contains 6153 individuals of the following races/ethnicities: white (n=2477), black (n=1540), Hispanic (n=1399), and Chinese American (n=767). All study participants gave informed consent and were followed for a median follow-up period of 8.5 years. Age, race/ethnicity, sex, and baseline measurements including hypertension (taking hypertension medication or with systolic blood pressure >140 mm Hg), diabetes (treated or untreated diabetes mellitus as determined by having fasting plasma glucose levels >126 mg/dL according to 2003 American Diabetes Association fasting criteria algorithm), lipid-lowering medication, and smoking status (former and current) were recorded. All related laboratory measurements and imaging data were obtained at baseline as well.

Genotyping

Participants in the original MESA cohort who consented to genetic analyses were genotyped in 2009 with use of the Affymetrix Human SNP array 6.0. Genotype quality control for these data included filtering on an SNP level call rate <95%, an individual level call rate <95%, and heterozygosity >53%, as described previously. The cleaned genotypic data were deposited with MESA phenotypic data into dbGaP as the MESA SHARe (SNP Health Association Resource) project (study accession phs000209.v2.p1) with 897 981 SNPs passing study-specific quality control. IMPUTE version 2.2.2 was used to perform imputation for the MESA SHARe participants by using the cosmopolitan 1000 Genomes Phase 1 v3 March 2012 reference set. All 1348 SNPs (35 genotyped, remainder imputed) in the ALOX5 gene were included in the analysis. SNPs with minor allele frequencies <0.01 and imputation quality <0.3 in a single race group were excluded.

Laboratory Measurements

Fasting plasma triglyceride, total cholesterol, and high-density lipoprotein cholesterol (HDL-C) concentrations were measured as described previously. Low-density lipoprotein-cholesterol (LDL-C) was calculated based on the Friedewald formula in participants with triglycerides <400 mg/dL. Plasma phospholipid AA (20:4, n-6), EPA (20:5, n-3), and DHA (22:6, n-3) were measured by using gas chromatography flame-ionization as described previously. The fatty acids were assayed in 2 batches in 2008 and then in 2012. A shift in fatty acid levels was observed between batches, and assay batch was therefore included as a covariate in the analysis. In terms of reproducibility, correlations of variance for fatty acids were as follows: AA (10.7%), EPA (7.6%), and DHA (8.5%).

Subclinical Atherosclerosis

The cIMT was assessed at visit 1 by using ultrasonography. Both common and internal cIMT values were included in the analysis. Trained technicians performed B-mode ultrasonography of the right and left near and far walls of the internal carotid and common carotid arteries by using the Logiq 700 ultrasound device (General Electric Medical Systems) as described previously. Maximal IMT values of the internal and common carotids were measured as the mean of the maximum IMT values of the near and far walls of the right and left sides. Reproducibility of IMT measurements has
previously been assessed by blinded replicate readings, performed by 2 readers. One reader reread 66 studies for an interreader correlation coefficient of 0.84 (n=66), and a second reader reread 48 studies, with a correlation coefficient of 0.86. The rescan and the reread coefficients of variation were 7.07% and 3.48%, respectively.19,20

**Incident Coronary Heart Disease**

Incident CHD was defined as the first occurrence of MI (n=150), resuscitated cardiac arrest (n=19), CHD death (n=70), or definite angina (n=158). Definite angina was defined as symptoms of typical chest pain and physician diagnosis of angina followed by percutaneous coronary intervention or coronary artery bypass graft surgery, evidence of ischemia on stress tests or resting ECG, or ≥70% obstruction on coronary angiography.

**Statistical Analysis**

The fatty acid measures (EPA and DHA) were log-transformed. Allele frequencies were assessed for each SNP and tested for Hardy-Weinberg equilibrium separately. SNPs that did not satisfy Hardy-Weinberg equilibrium were excluded. Multivariable linear regression was used to test for associations between cIMT and ALOX5 SNPs separately assuming an additive model, with or without SNP–fatty acid interaction. Robust standard error was used when assessing the significance of interactions. Assumptions of linear model were examined and confirmed by using residual plots. Cox proportional hazard regression was used to test for CHD–SNP associations. The proportional hazards assumption was examined by using the scaled Schoenfeld residuals.21

Age, sex, body mass index, smoking, systolic blood pressure, hypertension and lipid-lowering medication use, diabetes, cholesterol LDL, HDL, and (log-transformed) triglycerides, and batch of fatty acid measure (described earlier) were adjusted. All analyses were performed based on race/ethnicity, a subsequent meta-analysis was carried out to combine the association results, and the heterogeneity of effect size was further tested. Bonferroni correction was used to account for multiple testing of 1348 SNPs and in 4 race groups.

**Results**

Baseline characteristics for 6153 MESA participants, stratified by race/ethnicity, are shown in Table 1. Associations of 1348 ALOX5 SNPs with common cIMT, internal cIMT, and CHD events were determined. No significant associations in the cohort or within each race/ethnic group were detected. We then tested interactions among ALOX5 SNPs, the aforementioned outcome variables, and plasma levels of PUFAs AA,

Table 1. Characteristics of MESA Participants Across 4 Ethnic Groups at Baseline

|                     | Whites | Blacks | Hispanics | Chinese Americans |
|---------------------|--------|--------|-----------|--------------------|
| n                   | 2447   | 1540   | 1399      | 767                |
| Age, y              | 63 (54–71) | 63 (53–70) | 61 (53–69) | 62 (53–71)        |
| Sex (male), n       | 1169 (47.8%) | 708 (46.0%) | 677 (48.4%) | 377 (49.2%)       |
| BMI, n              | 27 (24–30) | 29 (26–34) | 29 (26–32) | 24 (22–26)        |
| Smoker, n           | 1373 (56.1%) | 850 (55.2%) | 644 (46.0%) | 191 (24.9%)       |
| Diabetes, n         | 423 (17.3%) | 500 (32.5%) | 461 (33.0%) | 238 (31.0%)       |
| Hypertension, n     | 949 (38.8%) | 916 (69.5%) | 577 (41.2%) | 287 (37.4%)       |
| LDL-C, mg/dL        | 115 (96–137) | 115 (95–136) | 119 (97–139) | 113 (96–131)     |
| HDL-C, mg/dL        | 52 (41–61) | 52 (41–61) | 48 (39–54) | 49 (40–56)        |
| Triglycerides, mg/dL| 114 (77–164) | 90 (66–123) | 136 (97–193) | 124 (87–173)     |
| AA (% total)        | 11.3 (9.7–12.8) | 13.2 (11.6–14.8) | 10.9 (9.3–12.8) | 10.3 (8.9–11.8) |
| EPA (% total)       | 0.7 (0.5–1.0) | 0.8 (0.5–1.0) | 0.5 (0.4–0.7) | 0.9 (0.6–1.5)     |
| DHA (% total)       | 3.2 (2.5–4.2) | 4.1 (3.3–5.0) | 3.0 (2.3–3.8) | 5.0 (4.1–5.9)     |
| Common cIMT, mm     | 0.8 (0.7–1.0) | 0.9 (0.8–1.0) | 0.8 (0.7–0.9) | 0.8 (0.7–0.9)     |
| Internal cIMT, mm   | 0.9 (0.7–1.4) | 0.9 (0.7–1.3) | 0.8 (0.7–1.2) | 0.7 (0.6–0.9)     |
| CHD events, n       | 163 (6.7%) | 82 (5.3%) | 75 (5.4%) | 25 (3.3%)         |

Median (IQR) values are shown for continuous variables and as counts (%) for categorical variables. Smoker (former and current), diabetes (treated or untreated), hypertensive (systolic blood pressure ≥140 mm Hg or taking hypertension medication), AA indicates arachidonic acid; BMI, body mass index; CHD, coronary heart disease; cIMT, carotid intima-media thickness; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MESA, Multi-Ethnic Study of Atherosclerosis.
EPA, DHA, or their ratios (DHA+EPA):AA, EPA:AA, and DHA: AA. No significant interactions were observed after accounting for multiple testing.

Associations for all 1348 SNPs are reported in Supplementary Material. A sample of 7 common SNPs in the ALOX5 gene that were presented by Assimes et al10 was selected for presentation to directly compare results. The allele frequencies of these 7 ALOX5 SNPs are shown in Table 2. All minor allele frequencies exceeded 1%, with the exception of rs2228064 and rs2228065 in whites and rs41526545 in Chinese Americans.

Main and interaction effects are shown in Table 3 with SE and P-values specified. Regression coefficients are presented for associations between common or internal IMT outcomes and the specified fatty acid (EPA, DHA, or AA) as well as associations of the specified fatty acid with ALOX5 variants. Interactions of the ALOX5 variants, levels of specified fatty acid, and IMT are further indicated. No significant interactions were identified after corrections for multiple testing.

The marginal associations between 7 ALOX5 polymorphisms and CHD risk with plasma fatty acids serving as modifying variables are shown in Table 4. In the MESA cohort, only EPA was significantly associated with CHD risk, so only log-transformed EPA was considered as a modifying variable. Hazard ratios are indicated for associations between EPA and incident CHD as well as EPA and ALOX5 variants. The interactions of ALOX5 variants, EPA, and incident CHD are further specified. No associations were found among single SNPs and CHD, including rs12762303, which was previously reported to be tightly linked to promoter region SP1 tandem repeats variation in European Americans.10 Associations for all 1348 SNPs are reported in Supplementary Material.

**Discussion**

In the present study of 6153 apparently healthy MESA participants at baseline, associations among ALOX5 SNPs and subclinical atherosclerosis as well as CHD events were examined. Modifying influences of race/ethnicity and plasma PUFAs were also tested. Our results showed no significant associations between 1348 ALOX5 SNPs and the presence of subclinical atherosclerosis or the occurrence of clinical CHD events. The null findings persisted after including plasma levels of AA, EPA, and DHA as modifying variables.

The LOX-5 pathway generates key players in the inflammatory response including the series-4 leukotrienes, which have been shown to mediate chemotaxis and vascular permeability and maintain the overall inflammatory environment.22,23 As these processes are also hallmarks of atherogenesis, LOX-5 activity and ALOX5 genotypes have been proposed as potential contributors to disease. Human tissue studies as well as those using rodent models of atherosclerosis support a role for the LOX-5 leukotriene pathway for inducing atherosclerosis.4,6,7,24–27 Corresponding case-control studies in human subjects have reported positive associations between ALOX5 and atherosclerosis, though null findings have also been shown. In a cohort of 470 healthy, middle-aged individuals from the Los Angeles Atherosclerosis Study, participants with 2 copies of variant alleles (deletion or insertion of Sp1 motifs) of a tandem Sp1 binding motif polymorphism in the ALOX5 promoter region showed an increase in cIMT compared with those who carried the wild-type allele.8 This association was enhanced by dietary intake of AA and blunted by intake of long-chain omega-3 fatty acids EPA (20:5, n-3) and DHA (22:6, n-3). A follow-up study in a larger case-control population of Costa Rican individuals (1885 pairs) showed that the variant alleles of the ALOX5 Sp1 motifs were not associated with the occurrence of MI.11 However, once dietary PUFAs intake was included as a modifying variable, a significant MI risk was observed in subjects with high dietary AA intake, while EPA or DHA showed no modifying effect on the ALOX5–MI association.

In contrast to these results, subsequent studies have been unable to demonstrate a relationship between ALOX5 SNPs and atherosclerosis or CHD. These include a case-control study of MI in the United Kingdom28 and 2 case-control...
Table 3. Main and Interaction Effects With Subclinical Atherosclerosis are Shown for 6153 Participants of the MESA

| EPA | SNP ID | £ | SE  | £ Value | £ | SE  | £ Value | Interaction £ | SE  | £ Value |
|-----|--------|---|-----|---------|---|-----|---------|-------------|-----|---------|
| Common IMT | rs12762303 | 0.00097 | 0.0041 | 0.813 | –0.0049 | 0.0046 | 0.282 | –0.0087 | 0.006 | 0.149 |
|      | rs2228064 | –0.0021 | 0.0037 | 0.566 | 0.0068 | 0.0057 | 0.235 | –0.00026 | 0.0083 | 0.975 |
|      | rs41526545 | –0.0013 | 0.0037 | 0.724 | –0.0098 | 0.0055 | 0.075 | –0.0048 | 0.0079 | 0.544 |
|      | rs2029253 | –0.0053 | 0.0053 | 0.313 | –0.0021 | 0.0033 | 0.526 | 0.0036 | 0.0044 | 0.421 |
|      | rs28395866 | –0.0033 | 0.0037 | 0.384 | 0.0094 | 0.0051 | 0.064 | 0.0049 | 0.0069 | 0.474 |
|      | rs2228065 | –0.0016 | 0.0046 | 0.723 | 0.02 | 0.0096 | 0.037 | 0.0045 | 0.015 | 0.759 |
|      | rs2229136 | –0.0025 | 0.0037 | 0.508 | 0.011 | 0.0065 | 0.094 | 0.0022 | 0.0085 | 0.796 |
| Internal IMT | rs12762303 | –0.022 | 0.014 | 0.11 | –0.018 | 0.015 | 0.232 | –0.0095 | 0.019 | 0.626 |
|      | rs2228064 | –0.026 | 0.012 | 0.032 | –0.019 | 0.021 | 0.354 | 0.0027 | 0.03 | 0.929 |
|      | rs41526545 | –0.026 | 0.012 | 0.037 | 0.014 | 0.019 | 0.479 | –0.00067 | 0.027 | 0.98 |
|      | rs2029253 | –0.024 | 0.018 | 0.18 | 0.0086 | 0.012 | 0.46 | –0.0014 | 0.016 | 0.933 |
|      | rs28395866 | –0.031 | 0.012 | 0.012 | –0.0062 | 0.019 | 0.747 | 0.027 | 0.028 | 0.34 |
|      | rs2228065 | –0.022 | 0.015 | 0.142 | 0.069 | 0.038 | 0.074 | 0.014 | 0.047 | 0.768 |
|      | rs2229136 | –0.026 | 0.012 | 0.034 | 0.032 | 0.022 | 0.14 | 0.0045 | 0.031 | 0.882 |

| DHA | SNP ID | £ | SE  | £ Value | £ | SE  | £ Value | Interaction £ | SE  | £ Value |
|-----|--------|---|-----|---------|---|-----|---------|-------------|-----|---------|
| Common IMT | rs12762303 | –0.008 | 0.0069 | 0.243 | 0.0088 | 0.014 | 0.523 | –0.0084 | 0.0098 | 0.393 |
|      | rs2228064 | –0.013 | 0.0062 | 0.034 | –0.002 | 0.018 | 0.914 | 0.0075 | 0.013 | 0.569 |
|      | rs41526545 | –0.011 | 0.0063 | 0.087 | –0.0041 | 0.016 | 0.804 | 0.004 | 0.013 | 0.757 |
|      | rs2029253 | –0.0067 | 0.0084 | 0.425 | 0.0031 | 0.0095 | 0.742 | 0.0053 | 0.007 | 0.451 |
|      | rs28395866 | –0.015 | 0.0062 | 0.013 | –0.02 | 0.018 | 0.255 | 0.022 | 0.012 | 0.078 |
|      | rs2228065 | –0.0085 | 0.008 | 0.287 | 0.047 | 0.043 | 0.28 | –0.019 | 0.028 | 0.501 |
|      | rs2229136 | –0.011 | 0.0062 | 0.073 | 0.012 | 0.019 | 0.512 | –0.0013 | 0.014 | 0.923 |
| Internal IMT | rs12762303 | –0.061 | 0.023 | 0.0066 | 0.049 | 0.049 | 0.312 | –0.049 | 0.035 | 0.17 |
|      | rs2228064 | –0.078 | 0.021 | 0.00017 | –0.027 | 0.065 | 0.671 | 0.012 | 0.047 | 0.801 |
|      | rs41526545 | –0.066 | 0.021 | 0.0014 | 0.092 | 0.065 | 0.157 | –0.069 | 0.05 | 0.172 |
|      | rs2029253 | –0.078 | 0.029 | 0.0072 | 0.0066 | 0.034 | 0.847 | 0.00059 | 0.025 | 0.982 |
|      | rs28395866 | –0.083 | 0.021 | 0.000063 | –0.053 | 0.058 | 0.36 | 0.033 | 0.042 | 0.429 |
|      | rs2228065 | –0.048 | 0.025 | 0.051 | 0.189 | 0.157 | 0.229 | –0.085 | 0.103 | 0.409 |
|      | rs2229136 | –0.082 | 0.021 | 0.000092 | 0.015 | 0.063 | 0.818 | 0.015 | 0.047 | 0.751 |

| AA | SNP ID | £ | SE  | £ Value | £ | SE  | £ Value | Interaction £ | SE  | £ Value |
|----|--------|---|-----|---------|---|-----|---------|-------------|-----|---------|
| Common IMT | rs12762303 | 0.031 | 0.012 | 0.0066 | –0.057 | 0.048 | 0.238 | 0.022 | 0.02 | 0.265 |
|      | rs2228064 | 0.034 | 0.011 | 0.0025 | –0.044 | 0.059 | 0.451 | 0.019 | 0.023 | 0.408 |
|      | rs41526545 | 0.042 | 0.011 | 0.000083 | 0.039 | 0.065 | 0.553 | –0.019 | 0.027 | 0.469 |
|      | rs2029253 | 0.04 | 0.016 | 0.013 | 0.0042 | 0.032 | 0.896 | –0.0026 | 0.013 | 0.844 |
|      | rs28395866 | 0.029 | 0.011 | 0.009 | –0.103 | 0.055 | 0.06 | 0.043 | 0.022 | 0.047 |
|      | rs2228065 | 0.042 | 0.013 | 0.001 | 0.043 | 0.111 | 0.701 | –0.01 | 0.044 | 0.813 |
|      | rs2229136 | 0.037 | 0.011 | 0.00087 | –0.0033 | 0.066 | 0.96 | 0.0046 | 0.027 | 0.863 |

Continued
studies of coronary artery diseases in the United States. In the latter, Assimes et al genotyped 7 SNPs in ALOX5 in 1552 cases with clinically significant coronary artery disease and 1583 controls from the Atherosclerotic Disease, Vascular Function, and Genetic Epidemiology cohort and a subcohort of 479 individuals in the Coronary Artery Risk Development in Young Adults study. Although a nominally significant association was detected between SNP rs12762303 and coronary artery disease, the association could not be replicated in the multicenter ARIC cohort, with or without considering gene–dietary fatty acids interaction. Our results agree with this latter finding from ARIC that rs12762303 does not significantly associate with cIMT or CHD risk after adjustment for known risk factors of CHD.

A notable and intriguing aspect of 2 previous studies of ALOX5 is the purported nutrition–genetics interactions between gene variants and long-chain omega-6 and omega-3 fatty acids. Dwyer et al reported that the observed association between ALOX5 SP1 tandem variation and atherosclerosis was modified by dietary intakes of AA, EPA, and DHA. Increased AA intake enhanced the atherogenic effect of the non–wild-type ALOX5 genotype, while increased EPA and DHA intake rendered it nonsignificant. In a follow-up study in a Costa Rican population from the same author group, an ALOX5 gene–diet interaction was found with AA but not with EPA or DHA. To avoid relying on an estimate of fatty acid intake from dietary questionnaires, we determined the phospholipid fatty acid composition in all of 6153 MESA participants. Using this objective measure shown to relate to bioavailable fatty acids, we showed no significant interaction with the ALOX5 SNPs on their association with subclinical atherosclerosis or clinical CHD outcomes. These findings are in agreement with those from the ARIC cohort.

**Strengths and Limitations**

The present analysis included a large multiethnic population, and quantified fatty acids were available in all study participants. The interactions of ALOX5 variants, EPA, and CHD were shown in the last column. CHD indicates coronary heart disease; EPA, eicosapentaenoic acid; MESA, Multi-Ethnic Study of Atherosclerosis; RERI, relative excess risk as a result of interaction; SNP, single nucleotide polymorphism.

**Table 3. Continued**

| AA | SNP ID | Beta | SE  | P Value | Beta | SE  | P Value | Interaction |
|----|--------|------|-----|---------|------|-----|---------|------------|
| Internal IMT | rs12762303 | 0.04 | 0.038 | 0.301 | −0.404 | 0.149 | 0.0066 | 0.16 | 0.061 | 0.0094 |
|   | rs2228064 | 0.101 | 0.037 | 0.0058 | −0.012 | 0.19 | 0.951 | −0.0063 | 0.076 | 0.934 |
|   | rs41526545 | 0.069 | 0.035 | 0.048 | −0.349 | 0.206 | 0.091 | 0.149 | 0.086 | 0.083 |
|   | rs2029253 | 0.106 | 0.052 | 0.039 | 0.041 | 0.109 | 0.708 | −0.012 | 0.044 | 0.792 |
|   | rs28395866 | 0.096 | 0.036 | 0.0082 | −0.08 | 0.188 | 0.67 | 0.023 | 0.075 | 0.762 |
|   | rs2228065 | 0.08 | 0.042 | 0.056 | −0.052 | 0.418 | 0.901 | 0.044 | 0.168 | 0.793 |
|   | rs2229136 | 0.106 | 0.036 | 0.0034 | 0.307 | 0.201 | 0.127 | −0.113 | 0.081 | 0.16 |

Regression coefficients are shown for associations between (1) IMT outcomes (common or internal) and the specified fatty acid (arachidonic acid [AA], EPA, docosahexaenoic acid [DHA]); (2) the specified fatty acid and ALOX5 variants (SNP). Interactions of 7 selected ALOX5 variants, levels of fatty acids, and IMT are further indicated. SE and P-values are specified. EPA indicates eicosapentaenoic acid; IMT, intima-media thickness; MESA, Multi-Ethnic Study of Atherosclerosis; SNP, single nucleotide polymorphism.

**Table 4. Main Effect and Interaction Associations With Incident CHD in 6153 Participants of the MESA**

| SNP ID | EPA | SE  | P Value | SNP | SE  | P Value | Interaction | SE  | P Value | RERI |
|--------|-----|-----|---------|-----|-----|---------|------------|-----|---------|------|
| rs12762303 | 0.753 | 0.087 | 0.014 | 0.891 | 0.125 | 0.413 | 0.908 | 0.171 | 0.606 | −0.035 |
| rs2228064 | 0.7 | 0.076 | 0.001 | 0.922 | 0.179 | 0.675 | 1.34 | 0.342 | 0.256 | 0.241 |
| rs41526545 | 0.716 | 0.082 | 0.0036 | 0.975 | 0.152 | 0.871 | 1.11 | 0.247 | 0.644 | 0.083 |
| rs2029253 | 0.895 | 0.134 | 0.46 | 0.975 | 0.099 | 0.802 | 0.791 | 0.098 | 0.06 | −0.18 |
| rs28395866 | 0.715 | 0.078 | 0.0021 | 0.984 | 0.158 | 0.92 | 1.14 | 0.281 | 0.596 | 0.103 |
| rs2228065 | 0.681 | 0.111 | 0.019 | 1.31 | 0.419 | 0.392 | 1.57 | 0.675 | 0.294 | 0.41 |
| rs2229136 | 0.68 | 0.074 | 0.0004 | 1.22 | 0.191 | 0.206 | 1.48 | 0.356 | 0.1 | 0.331 |

Hazard ratios are shown for associations between (1) incident CHD and EPA and (2) EPA and ALOX5 SNPs. The interactions of ALOX5 variants, EPA, and CHD are shown in the last column. CHD indicates coronary heart disease; EPA, eicosapentaenoic acid; MESA, Multi-Ethnic Study of Atherosclerosis; RERI, relative excess risk as a result of interaction; SNP, single nucleotide polymorphism.

DOI: 10.1161/JAHA.115.002814
participants. However, it must be acknowledged that only ALOX5 genotyping was performed and no corresponding evidence of LOX-5 protein expression or enzymatic activity was measured. In addition, we did not use an autosomal recessive model for assessing the effect of SP1 tandem variants but instead used a logistic additive model to test the impact of these SNPs. A final limitation of the present analysis is that the vast majority (97.4%) of the 1348 ALOX5 SNPs were imputed but were subsequently filtered based on imputation quality.

Conclusions

While previous studies using cell culture, animal models, and human case-control designs have supported a role for LOX-5 pathways in the development of atherosclerosis, we found that ALOX5 SNPs were not associated with either the presence of atherosclerosis or CHD incidence over time—
ey even after considering interactions with plasma fatty acids and race/ethnicity. LOX-5 protein expression and enzyme activity likely contribute to disease pathogenesis, but ALOX5 SNPs do not appear to be related to these disease outcomes.

Acknowledgments

The authors thank the other investigators, staff, and participants of MESA for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org.

Sources of Funding

MESA and the MESA SHARE project are conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with MESA investigators. Support for MESA is provided by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-001079, UL1-TR-000040, and DK063491. Funding for SHARE genotyping was provided by National Heart, Lung, and Blood Institute Contract N02-HL-55272. Genotyping was performed at Affymetrix and the Broad Institute of Harvard and MIT using the Affymetrix Genome-Wide Human SNP Array 6.0.

Disclosures

None.

References

1. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294:1871–1875.
2. Funk CD. Leukotriene modifiers as potential therapeutic agents for cardiovascular disease. Nat Rev Drug Discov. 2005;4:664–672.
3. Lützer K, Funk CD, Habenicht AJ. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta. 2005;1736:30–37.
4. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Röbenek H, Salbach P, Kuhn H, Radmark O, Samuelsen B, Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA. 2003;100:1238–1243.
5. Cicci C, Sessarego T, Frangioni M, Iacono F, Rezzi P, Bucci M, Cuccurullo F, Buicci M, Cuccurullo F, Prescott SM, Stafforini DM. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665–1670.
22. Dahlén SE, Björk J, Hedqvist P, Arfors KE, Hammarström S, Lindgren JA, Samuelsson B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA. 1981;78:3887–3891.

23. Björk J, Hedqvist P, Arfors KE. Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes. Inflammation. 1982;6:189–200.

24. Tabibiazar R, Wagner RA, Spin JM, Ashley EA, Narasimhan B, Rubin EM, Efron B, Tsao PS, Tibshirani R, Quertermous T. Mouse strain-specific differences in vascular wall gene expression and their relationship to vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:302–308.

25. Tabibiazar R, Wagner RA, Ashley EA, King JY, Ferrara R, Spin JM, Sanan DA, Narasimhan B, Tibshirani R, Tsao PS, Efron B, Quertermous T. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol Genomics. 2005;22:213–226.

26. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120–126.

27. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med. 2004;14:191–195.

28. González P, Reguero JR, Lozano I, Morís C, Coto E. A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int J Immunogenet. 2007;34:127–130.